European review for medical and pharmacological sciences · 2019
Influence of miR-26b on hepatic cirrhosis and portal pressure in rats with cirrhotic portal hypertension by targeting hENT1 depending on RhoA/ROCK-1 pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Simşek-Kaya Göksel, Özbek Elvan, Kalkan Yildiray, Yapici Günay, Dayi Ertunç, Demirci Tuba
Аннотация
INTRODUCTION: Type 2 diabetes (T2D) is linked to a higher risk of cardiovascular disease (CVD). However, evidence on the impact of different short‑chain fatty acids (SCFAs) on subclinical CVD is limited in patients with T2D.
OBJECTIVES: We aimed to investigate the associations between circulating SCFA levels and subclinical CVD in patients with T2D.
PATIENTS AND METHODS: This cross‑sectional study enrolled 326 patients with T2D from November 2016 to June 2020. The levels of 9 SCFAs, including formate, acetate, propionate, butyrate, isobutyrate, methylbutyrate, valerate, isovalerate, and methylvalerate, were measured in fasting serum using liquid chromatography-mass spectrometry. Cardiac structure and function were evaluated on echocardiography. Ankle‑brachial index (ABI) and brachial‑ankle pulse wave velocity, as a parameter of arterial stiffness, were measured. Multivariable linear and logistic regression models were adjusted for traditional risk factors including cholesterol and glycated hemoglobin (HbA1c) levels.
RESULTS: Mean (SD) age of the patients was 63.5 (10.4) years and 56.4% were men. Median (interquartile range) HbA1c level was 7% (6.5%-7.9%). Adjusted odds ratios of left ventricular hypertrophy for comparison of the first and third tertile levels of formate and isobutyrate were 2.39 and 2.6, respectively. Higher butyrate / isobutyrate ratio was significantly associated with a decreased risk of diastolic dysfunction. An inverse relationship between valerate level and arterial stiffness was found. The patients with the highest tertile level of butyrate had a lower risk of abnormal ABI.
CONCLUSIONS: Our study demonstrates that serum SCFAs are potential biomarkers of the early stage of cardiovascular remodeling in patients with T2D.
OBJECTIVES: We aimed to investigate the associations between circulating SCFA levels and subclinical CVD in patients with T2D.
PATIENTS AND METHODS: This cross‑sectional study enrolled 326 patients with T2D from November 2016 to June 2020. The levels of 9 SCFAs, including formate, acetate, propionate, butyrate, isobutyrate, methylbutyrate, valerate, isovalerate, and methylvalerate, were measured in fasting serum using liquid chromatography-mass spectrometry. Cardiac structure and function were evaluated on echocardiography. Ankle‑brachial index (ABI) and brachial‑ankle pulse wave velocity, as a parameter of arterial stiffness, were measured. Multivariable linear and logistic regression models were adjusted for traditional risk factors including cholesterol and glycated hemoglobin (HbA1c) levels.
RESULTS: Mean (SD) age of the patients was 63.5 (10.4) years and 56.4% were men. Median (interquartile range) HbA1c level was 7% (6.5%-7.9%). Adjusted odds ratios of left ventricular hypertrophy for comparison of the first and third tertile levels of formate and isobutyrate were 2.39 and 2.6, respectively. Higher butyrate / isobutyrate ratio was significantly associated with a decreased risk of diastolic dysfunction. An inverse relationship between valerate level and arterial stiffness was found. The patients with the highest tertile level of butyrate had a lower risk of abnormal ABI.
CONCLUSIONS: Our study demonstrates that serum SCFAs are potential biomarkers of the early stage of cardiovascular remodeling in patients with T2D.